AD-SCAP: ADaptive platform trial for Severe Community Acquired Pneumonia
ATTEND THE FINAL INTERACTIVE WEBINAR ABOUT THE NEW AD-SCAP TRIAL…
Community-acquired pneumonia (CAP) is the most common cause of sepsis and ARDS. Patients with CAP often develop acute respiratory failure that requires ventilatory support in the ICU. Conducted by the Platform foR European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium, AD-SCAP will utilise an exciting adaptive study design to determine optimal antimicrobial treatment, immuno-modulatory and ventilation strategies to increase survival at hospital discharge.
Patients enrolled in this platform trial to be conducted in more than 150 ICUs across Europe will be randomised in three treatment domains with only one goal: build an infrastructure for rapidly obtaining evidence for the optimal management of ICU patients with CAP. It is time to fuse research and clinical practice!
Watch this icTV interview with investigators Derek Angus and Alistair Nichol about the rationale for PREPARE and this innovative new trial:
Want to find out more about this exciting new adaptive trial?
Attend our interactive webinar and learn how to register your ICU…
(THIS SESSION IS OPEN FOR ALL MEMBERS AND NON-MEMBERS TO ATTEND!)
All participants are welcome to register through the link below:
April 26th, 15.00 Brussels time
PREPARE AD-SCAP: Ethics (AN) and Study logistics
Registration is now closed.
For more information about AD-SCAP, please visit our dedicated webpage